Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Oramed Pharmaceuticals to Present at the 10th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2011

May 11, 2011

JERUSALEM, May 11, 2011 /PRNewswire-FirstCall/ — Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery
systems, announced today that it was chosen to present at the 10th National
Life Science & Technology Week ILSI-BIOMED Conference, Israel 2011. The
presentation will be given by Nadav Kidron, Chief Executive Officer of
Oramed, on Tuesday, May 24th during the BioPharma Session at 12:50 p.m. (IDT)
at the David Intercontinental Hotel in Tel-Aviv, Israel.

Event: National Life Science & Technology Week ILSI-BIOMED Conference,
Israel 2011

Date: Tuesday, May 24 2011

Time: 12:50 p.m. (IDT), or 5:50 a.m. (EST)

For more information about the upcoming ILSI Biomed conference, please
visit the following website: http://www2.kenes.com/biomed/Pages/Home.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed’s technology is based on
over 25 years of research by top research scientists at Jerusalem’s Hadassah
Medical Center. The Company’s corporate and R&D headquarters are based in
Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements Some of the statements contained in this press
release are forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company’s ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.

    Company and Investor Relations Contact:
    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-4318
    Office: Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


Source: newswire